ASCO GU 2022: Patient-reported experience of kidney cancer from the IKCC
The incidence of renal cell carcinoma (RCC) is rising globally, [...]
ASCO GU 2022: Choosing between combination treatments for advanced kidney cancer
Combination therapies have revolutionised the first-line treatment of metastatic clear [...]
ASCO GU 2022: Treatment of sarcomatoid kidney cancer with immunotherapy
Metastatic sarcomatoid clear cell RCC is an aggressive type of [...]
ASCO GU 2022: Cytoreductive nephrectomy for patients with lung metastases
Cytoreductive nephrectomy is the surgical removal of the tumour to [...]
ASCO GU 2022: Cytoreductive nephrectomy for patients with tumour thrombus
Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number [...]
ASCO GU 2022: Pembrolizumab as adjuvant therapy for kidney cancer
Nephrectomy is the standard of care for advanced renal cell [...]
ASCO GU 2022: Neoadjuvant cabozantinib clinically active in kidney cancer
Results from a phase 2 study were presented at the [...]
ASCO GU 2022: Neoadjuvant avelumab/axitinib shows promise in kidney cancer
Results from the NeoAvAx clinical trial were presented at the [...]
‘Levelling up’: What should it mean for cancer?
The Government has set out plans for ‘levelling up’ in [...]
Government’s ‘War on Cancer’
The Secretary of State for Health and Social Care has [...]
